- Home
- TRNO vs MIRM Comparison
TRNO vs MIRM Comparison
Compare TRNO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNO | MIRM |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.7B |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TRNO | MIRM |
|---|---|---|
| Price | $65.59 | $121.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $67.83 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 842.1K | 785.1K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 103.65 | 74.59 |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $476,383,000.00 | $19,138,000.00 |
| Revenue This Year | $8.42 | $26.22 |
| Revenue Next Year | $9.10 | $22.04 |
| P/E Ratio | $99.05 | ★ N/A |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $47.89 |
| 52 Week High | $67.83 | $119.49 |
Technical Indicators
Market Signals| Indicator | TRNO | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 78.30 |
| Support Level | $63.63 | $87.93 |
| Resistance Level | $67.18 | N/A |
| Average True Range (ATR) | 1.62 | 4.98 |
| MACD | -0.01 | 2.49 |
| Stochastic Oscillator | 58.06 | 92.80 |
Price Performance
Historical ComparisonAbout TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.